跳到正文
Absci· @abscibio · X·· 13 天前AI 评分32
AI 导读

Absci 的 AI 设计抗体 ABS-201 登上《时尚先生》雄激素性脱发治疗报道,目前处于 Phase 1/2a 试验。ABS-201 采用靶向催乳素受体的新型在研作用机制,与现有获批方案不同。文章指出,过去 30 年获批的模式性脱发治疗创新有限。

正文 · 原文

Absci’s ABS-201 program was featured in a recent @esquire magazine article on the unmet need in androgenetic alopecia treatments. As the piece notes, approved treatments for pattern hair loss have seen limited innovation in the last 30 years. ABS-201, an AI-designed antibody from Absci currently in Phase 1/2a trials, takes a different approach: a novel, investigational mechanism of action targeting the prolactin receptor.

Read the article "The Bald Truth About the Generative Era of Hair Loss" to learn more about the treatment landscape and patient impact of pattern hair loss. https://esquire.com.au/the-bald-truth-about-the-generative-era-of-hair-loss

来源:Absci · x.com